FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.
You may also be interested in...
FDA’s Early Breast Cancer pCR Final Guidance Stresses One Trial
Final guidance from FDA on accelerated approval pathway based on pathological complete response in neoadjuvant breast cancer clarifies that one large trial is the “default” for most applications.
Partnering For Cures: What’s The Equation For Success?
That helping patients ultimately will lead to return for investors was the underlying theme of this year’s Partnering For Cures conference in New York Nov. 3-5. Panels looked at issues pertaining to mental health, biotech funding, finding a cure for lupus and clinical trial protocols for cardiovascular disease.
Oncologists Willing To Embrace pCR, Despite Potential Risks, ASCO Survey Finds
Ahead of Perjeta vote, impromptu survey of clinicians at ASCO Breast Cancer Symposium debate signals readiness to prescribe neoadjuvant drugs, based on pathological complete response data. ASCO President Clifford Hudis cautions of “serious risks to societal well-being with this approach.”